MDxHealth (MDXH) Stock Price, News & Analysis

Company Overview

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Key Stats

• Today's Range: $1.82 to $1.86
• 50-Day Range: $1.81 to $2.47
• 52-Week Range: $1.55 to $3.85
• Volume: 13,874 shs
• Average Volume: 97,795 shs
• Market Capitalization: $87.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

MDxHealth Stock Analysis - MarketRank™

MDxHealth scored higher than 57% of companies evaluated by MarketBeat, and ranked 472nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MDxHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MDxHealth has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MDxHealth are expected to grow in the coming year, from ($1.15) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MDxHealth is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MDxHealth is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MDxHealth has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MDxHealth has recently decreased by 30.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MDxHealth does not currently pay a dividend.

Dividend Growth

MDxHealth does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.08% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MDxHealth has recently decreased by 30.36%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MDxHealth this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for MDXH on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added MDxHealth to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MDxHealth insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.70% of the stock of MDxHealth is held by insiders.

MDXH Stock Analysis - Frequently Asked Questions

How have MDXH shares performed this year?

MDxHealth's stock was trading at $2.37 at the start of the year. Since then, MDXH shares have decreased by 22.2% and is now trading at $1.8450.
View the best growth stocks for 2025 here.

When did MDxHealth's stock split?

MDxHealth's stock reverse split before market open on Friday, December 29th 2023. The 1-10 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did MDxHealth IPO?

MDxHealth (MDXH) raised $45 million in an initial public offering on Thursday, November 4th 2021. The company issued 3,750,000 shares at a price of $12.00 per share.

Who are MDxHealth's major shareholders?

MDxHealth's top institutional investors include Bleichroeder LP (15.60%), AWM Investment Company Inc. (9.98%), Samjo Management LLC (3.86%) and Perkins Capital Management Inc. (2.08%).
View institutional ownership trends.

How do I buy shares of MDxHealth?

Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MDxHealth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MDxHealth investors own include Cognition Therapeutics (CGTX), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), PHX Minerals (PHX), PayPal (PYPL), Arcadia Biosciences (RKDA) and Alimera Sciences (ALIM).

Company Calendar

• Today: 2/21/2025
• Next Earnings (Estimated): 5/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MDXH
• CUSIP: N/A
• CIK: 1872529
• Web: mdxhealth.com
• Phone: 324-364-2070
• Fax: 32042597875
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +279.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-43,100,000.00
• Net Margins: -49.52%
• Pretax Margin: -49.12%
• Return on Equity: -1,077.84%
• Return on Assets: -28.82%

Debt

• Debt-to-Equity Ratio: 3.14
• Current Ratio: 1.54
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: $70.19 million
• Price / Sales: 1.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.62 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 47,290,000
• Free Float: 46,484,000
• Market Cap: $87.25 million
• Optionable: Not Optionable
• Beta: 1.34